PRICED Act
Bill journey · stage 2 of 5
Under committee review
What it doesSummary introduced in house (Jun 20, 2019)
Price Relief, Innovation, and Competition for Essential Drugs Act or the PRICED Act
This bill allows biosimilars to be marketed five years after the reference brand-name biological product is licensed. Currently, brand-name biological products are provided a 12-year marketing-exclusivity period.
This shortened marketing-exclusivity period applies only to biological products licensed by the Food and Drug Administration after enactment of this bill.
What just happenedJun 21, 2019
Referred to the Subcommittee on Health.
Who’s behind it
- Introduced in HouseJun 20, 2019
- Jun 21, 2019Committee
Referred to the Subcommittee on Health.
Health Subcommittee - Jun 20, 2019IntroReferralH11100
Referred to the House Committee on Energy and Commerce.
Energy and Commerce Committee - Jun 20, 2019IntroReferralIntro-H
Introduced in House
- Jun 20, 2019IntroReferral1000
Introduced in House